Dennis M. Mcgrath - 19 Sep 2025 Form 4/A - Amendment Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Reporting relationship: Director
Issuer ticker: CTOR
Reported as of: 19 Sep 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 22 Dec 2025, 16:10:07 UTC
Original report date: 23 Sep 2025
Prior SEC filing: 15 Sep 2025
Next SEC filing: 02 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander M. Donaldson, by Power of Attorney

Key filing fact

Dennis M. Mcgrath filed Form 4/A - Amendment for CITIUS ONCOLOGY, INC. (CTOR) on 22 Dec 2025.

Key facts

This page summarizes Dennis M. Mcgrath's Form 4/A - Amendment filing for CITIUS ONCOLOGY, INC. (CTOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Dec 2025, 16:10.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001269340 Primary reporting owner

MCGRATH DENNIS M

Relationship: Director
Address: C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD
Signature: /s/ Alexander M. Donaldson, by Power of Attorney
Signature date: 22 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTOR transaction

Common Stock

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 19 Sep 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.